Abstract
Vaccinia virus (VACV) is an enigma, for it is the only vaccine to have eradicated a human disease, smallpox, and yet its origin and natural host remain unknown. After the eradication of smallpox, VACV has continued to be studied intensively because of the potential use of recombinant VACVs as vaccines against other infectious diseases, and because it is an excellent model for studying virus-host interactions. This short article considers some of the strategies used by VACV to suppress the host innate immune response to infection. These strategies include proteins that are secreted from infected cells to bind complement factors, cytokines, chemokines or interferons, and intracellular proteins that can synthesize steroid hormones, or block apoptosis or innate signalling pathways leading to production of inflammatory mediators.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aguado, B., Selmes, I. P. & Smith, G. L. (1992) Nucleotide sequence of 21.8 kbp of variola major virus strain Harvey and comparison with vaccinia virus. J Gen Virol, 73, 2887–902.
Alcami, A. & Smith, G. L. (1992) A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell, 71, 153–67.
Alcami, A. & Smith, G. L. (1996) A mechanism for the inhibition of fever by a virus. Proc Natl Acad Sci USA, 93, 11029–34.
Aoyagi, M., Zhai, D., Jin, C., Aleshin, A. E., Stec, B., Reed, J. C. & Liddington, R. C. (2007) Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci, 16, 118–24.
Bartlett, N., Symons, J. A., Tscharke, D. C. & Smith, G. L. (2002) The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J Gen Virol, 83, 1965–76.
Blanchard, T. J., Alcami, A., Andrea, P. & Smith, G. L. (1998) Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol, 79, 1159–67.
Chen, R. A., Jacobs, N. & Smith, G. L. (2006) Vaccinia virus strain Western Reserve protein B14 is an intracellular virulence factor. J Gen Virol, 87, 1451–8.
Chen, R. A., Ryzhakov, G., Cooray, S., Randow, F. & Smith, G. L. (2008) Inhibition of IkappaB kinase by vaccinia virus virulence factor B14. PLoS Pathog, 4, e22.
Clark, R. H., Kenyon, J. C., Bartlett, N. W., Tscharke, D. C. & Smith, G. L. (2006) Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol, 87, 29–38.
Cooray, S., Bahar, M. W., Abrescia, N. G., Mcvey, C. E., Bartlett, N. W., Chen, R. A., Stuart, D. I., Grimes, J. M. & Smith, G. L. (2007) Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol, 88, 1656–66.
Diperna, G., Stack, J., Bowie, A. G., Boyd, A., Kotwal, G., Zhang, Z., Arvikar, S., Latz, E., Fitzgerald, K. A. & Marshall, W. L. (2004) Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem, 279, 36570–8.
Downie, A. W. (1939) Immunological relationship of the virus of spontaneous cowpox to vaccinia virus. Br. J. Exp. Pathol., 20, 158–76.
Esposito, J. J., Sammons, S. A., Frace, A. M., Osborne, J. D., Olsen-Rasmussen, M., Zhang, M., Govil, D., Damon, I. K., Kline, R., Laker, M., Li, Y., Smith, G. L., Meyer, H., Leduc, J. W. & Wohlhueter, R. M. (2006) Genome sequence diversity and clues to the evolution of variola (smallpox) virus. Science, 313, 807–12.
Fenner, F., Anderson, D. A., Arita, I., Jezek, Z. & Ladnyi, I. D. (1988) Smallpox and Its Eradication, World Health Organisation, Geneva.
Goebel, S. J., Johnson, G. P., Perkus, M. E., Davis, S. W., Winslow, J. P. & Paoletti, E. (1990) The complete DNA sequence of vaccinia virus. Virology, 179, 247–66, 517–63.
Graham, S. C., Bahar, M. W., Cooray, S., Chen, R. A. J., Whalen, D. M., Abrescia, N. G. A., Alderton, D., Owens, R. J., Stuart, D. I., Smith, G. L. & Grimes, J. M. (2008) Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to inhibit NF-kappa B rather than apoptosis. Plos Pathogens, 4, e100128.
Hashizume, S., Yoshizawa, H., Morita, M. & Suzuki, K. (1985) Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain. In Quinnan, G. V. (ed.), Vaccinia viruses as vectors for vaccine antigens. Elsevier, New York.
Jenner, E. (1798) An Enquiry into the Causes and Effects of Variolae Vaccinae, a Disease Discovered in some Western Countries of England, particularly Gloucestershire, and known by the Name of Cow Pox., London, Reprinted by Cassell, 1896.
Kalverda, A. P., Thompson, G. S., Vogel, A., Schroder, M., Bowie, A. G., Khan, A. R. & Homans, S. W. (2009) Poxvirus K7 protein adopts a Bcl-2 fold: biochemical mapping of its interactions with human DEAD box RNA helicase DDX3. J Mol Biol, 385, 843–53.
Kotwal, G. J., Hugin, A. W. & Moss, B. (1989) Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800-Da secreted protein. Virology, 171, 579–87.
Kotwal, G. J. & Moss, B. (1988) Analysis of a large cluster of nonessential genes deleted from a vaccinia virus terminal transposition mutant. Virology, 167, 524–37.
Kvansakul, M., Yang, H., Fairlie, W. D., Czabotar, P. E., Fischer, S. F., Perugini, M. A., Huang, D. C. & Colman, P. M. (2008) Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ, 15, 1564–71.
Lane, J. M., Ruben, F. L., Neff, J. M. & Millar, J. D. (1969) Complications of smallpox vaccination, 1968. National surveillance in the United States. N Engl J Med, 281, 1201–8.
Mackett, M. & Archard, L. C. (1979) Conservation and variation in Orthopoxvirus genome structure. J Gen Virol, 45, 683–701.
Mackett, M., Smith, G. L. & Moss, B. (1982) Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA, 79, 7415–9.
Moore, J. B. & Smith, G. L. (1992) Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor. EMBO J, 11, 3490.
Moss, B. (2007) Poxviridae: the viruses and their replicaton. In Knipe, D. M. (ed.), Fields virology. 5th ed., Lippincott Williams & Wilkins, Philadelphia, PA.
Moss, B., Winters, E. & Cooper, J. A. (1981) Deletion of a 9,000-base-pair segment of the vaccinia virus genome that encodes nonessential polypeptides. J Virol, 40, 387–95.
Panicali, D., Davis, S. W., Mercer, S. R. & Paoletti, E. (1981) Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol, 37, 1000–10.
Panicali, D., Davis, S. W., Weinberg, R. L. & Paoletti, E. (1983) Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci USA, 80, 5364–8.
Panicali, D. & Paoletti, E. (1982) Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA, 79, 4927–31.
Perkus, M. E., Piccini, A., lipinskas, B. R. & Paoletti, E. (1985) Recombinant vaccinia virus: immunization against multiple pathogens. Science, 229, 981–4.
Reading, P. C., Moore, J. B. & Smith, G. L. (2003) Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection. J. Exp. Med., 197, 1269–78.
Seet, B. T., Johnston, J. B., Brunetti, C. R., Barrett, J. W., Everett, H., Cameron, C., Sypula, J., Nazarian, S. H., Lucas, A. & Mcfadden, G. (2003) Poxviruses and immune evasion. Annu Rev Immunol, 21, 377–423.
Smith, G. L. (1999) Vaccinia virus immune evasion. Immunol. Lett, 65, 55–62.
Smith, G. L. & Chan, Y. S. (1991) Two vaccinia virus proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily. J Gen Virol, 72, 511–8.
Smith, G. L., Chan, Y. S. & Howard, S. T. (1991) Nucleotide sequence of 42 kbp of vaccinia virus strain WR from near the right inverted terminal repeat. J Gen Virol, 72, 1349–76.
Smith, G. L., Mackett, M. & Moss, B. (1983a) Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature, 302, 490–5.
Smith, G. L. & Moss, B. (1983) Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene, 25, 21–8.
Smith, G. L., Murphy, B. R. & Moss, B. (1983b) Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci USA, 80, 7155–9.
Spriggs, M. K., Hruby, D. E., Maliszewski, C. R., Pickup, D. J., Sims, J. E., Buller, R. M. & Vanslyke, J. (1992) Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell, 71, 145–52.
Sroller, V., Kutinova, L., Nemeckova, S., Simonova, V. & Vonka, V. (1998) Effect of 3-beta-hydroxysteroid dehydrogenase gene deletion on virulence and immunogenicity of different vaccinia viruses and their recombinants. Arch Virol, 143, 1311–20.
Staib, C., Kisling, S., Erfle, V. & Sutter, G. (2005) Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol, 86, 1997–2006.
Stickl, H. & Hochstein-Mintzel, V. (1971) [Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus (“MVA virus”)]. Munch Med Wochenschr, 113, 1149–53.
Tscharke, D. C., Reading, P. C. & Smith, G. L. (2002) Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J Gen Virol, 83, 1977–86.
Acknowledgements
The author is most grateful to the conference organisers for the kind invitation to visit Israel and attend the 46th Oholo Conference. The work in the author’s laboratory has been supported by grants from the Wellcome Trust, the Medical Research Council of UK. GLS is a Wellcome Principal Research Fellow.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this paper
Cite this paper
Smith, G.L. (2010). Inhibitors of Innate Immunity from Vaccinia Virus. In: Shafferman, A., Ordentlich, A., Velan, B. (eds) The Challenge of Highly Pathogenic Microorganisms. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9054-6_13
Download citation
DOI: https://doi.org/10.1007/978-90-481-9054-6_13
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-9053-9
Online ISBN: 978-90-481-9054-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)